Online consultations available nationwide, with home delivery across Japan.
International patients are very welcome. Customs certificates for returning travelers are also available.
- We use GLP-1 medications daily in our diabetes practice, giving us thorough knowledge of the drug’s properties, effects, and risks
- Comprehensive management of side effects (nausea, gastrointestinal symptoms). As internists, we can prescribe anti-nausea medication and additional treatments as needed
- 血糖、血壓、血脂等生活習慣病指標一併管理
- 睡眠呼吸中止症（肥胖常見合併症）也在本院接受治療
- We provide 在全面考慮健康的同時支持減重, not just aesthetics
What Is Wegovy?
Wegovy (generic name: semaglutide 2.4mg) is a GLP-1 receptor agonist officially approved in Japan for obesity treatment in 2023. With once-weekly subcutaneous injections, the STEP 1 clinical trial (1,961 participants, 68 weeks) confirmed an average weight reduction of approximately 14.9%.
It acts directly on the brain’s satiety center to suppress appetite, physiologically creating a state where you feel less hungry and are satisfied with smaller portions — supporting weight loss without relying on willpower or strict dieting.
適合哪些人？
- Those seeking significant weight loss (10 kg or more)
- Those for whom other GLP-1 medications (Rybelsus, Ozempic, etc.) were insufficiently effective
- Those with BMI ≥ 27 with comorbidities such as hypertension, diabetes, or dyslipidemia
- Those with BMI ≥ 35
- Those who want to minimize effort with a once-weekly injection
- Those who have repeatedly tried conventional diets without achieving lasting results
哪些人不能使用？
- Those with a history of pancreatitis
- Those with a personal or family history of medullary thyroid carcinoma or MEN2
- 正在懷孕、計劃懷孕或哺乳的人
- BMI低於18.5的人
- Those with severe gastrointestinal disorders
常見副作用
The most common side effects are gastrointestinal symptoms such as nausea, diarrhea, and constipation. Most resolve within 2–4 weeks after starting treatment. We can prescribe anti-nausea medication if needed.
| 副作用 | 頻率 | 處理方法 |
|---|---|---|
| 噁心 | ~20–30% | 少量多次進食；止吐藥 |
| 腹瀉 | ~10–20% | 補充水分；整腸藥 |
| 便秘 | ~10–20% | 補充水分、膳食纖維、瀉藥 |
| 頭痛 / 疲勞 | ~5–10% | 觀察 |
| 急性胰臟炎（罕見） | <0.1% | 出現嚴重上腹/背部疼痛時立即就醫 |
費用（含稅，運費另計）
運費：¥35,000以上免費 / ¥35,000以下¥1,500 / 不可退貨 / 付款：信用卡、銀行轉帳或現金
就診流程
💊 問診費用
¥0 — 您已確知所需藥品及劑量
¥5,500 — 您希望討論藥品選擇、劑量或減重計畫 （日文或英文）
🏥 來院就診（北海道札幌市中央區）
🖥 線上問診（全國對應）
-
預約
點擊此處進行預約。
完成後，我們將透過電子郵件傳送診療用網址。
※ 若未收到郵件，請確認垃圾郵件資料夾。 -
線上診療
無需安裝任何應用程式！點擊郵件中的網址即可。
將透過視訊通話進行本人確認。（※ 依據日本厚生勞動省遠距醫療指引）
請準備附有照片的身份證明文件。 -
付款
僅限信用卡 -
配送
線上診療結束後進行結算，寄送至您指定的地址。
可寄送至住家、公司或飯店等全國各地。不支援海外配送。
※ 可為歸國旅客開具海關證明。※ 不支持國際配送。
常見問題
- Q. 接受健康保險嗎？
- 在沒有糖尿病診斷的情況下用於減重時，治療為自費（私人）。 已診斷為糖尿病的患者可能有資格享受保險覆蓋。
- Q. How much weight can I expect to lose?
- In the STEP 1 clinical trial, an average of approximately 14.9% weight loss was confirmed. For a person weighing 80 kg, that equates to approximately 12 kg. Individual results may vary.
- Q. How does Wegovy compare to Mounjaro?
- Mounjaro (tirzepatide), with its dual GLP-1/GIP action, has shown greater weight reduction (avg. over 20%) than Wegovy. If you are looking for stronger weight loss, Mounjaro may be the better choice.
- Q. 停藥後會反彈嗎？
- 停藥後食欲可能恢復，有可能體重反彈。在治療期間養成健康飲食習慣是防止反彈的關鍵。
- Q. 外國患者可以接受治療嗎？
- 是的，可提供英語服務。我們還可以在您返回本國時為您出具海關申報所需的診斷證明書。
- Q. Wegovy（索馬魯肽）有哪些副作用？
- 常見副作用包括：噁心、腹瀉、便秘、嘔吐、腹痛、疲倦、頭痛、頭暈、注射部位反應、急性胰臟炎、腸阻塞、膽道疾病、低血糖、急性腎損傷等。
- Q. 線上看診後，藥品何時送達？
- 付款在線上看診期間完成。藥品將於發貨日後第二天送達（全國配送，北海道至沖繩）。
發貨日因看診時間而異。
以下情況可能導致延遲：看診時間 發貨日 週一・週二・週四・週五 11:30前 當天發貨 其他（11:30後・週三・週六・休診日） 次診療日發貨
・批發商庫存不足時
・颱風・大雪等惡劣天氣導致的配送延誤
預約線上或來院診療
預約 / 申請[Physician Explanation] Wegovy (Semaglutide): Effects, 副作用s, and STEP Trial Data